Right now the FDA has approved the Calypso for prostate cancer, but as you mentioned there's tremendous interest around the country and a lot of the places that have Calypso already in there are started to do a variety of work, clinical investigational work applying it to other organs in the body that move. So there is a great deal of hope and promise that this same technology that's now in use routinely for the prostate will eventually become in routine use for other common cancers where there may be motion involved as well, such as breast cancer and obviously lung cancer and other tumors in the abdomen where with breathing motion is pretty common as well. So there is a tremendous interest in it. There's a lot of work going on around the country already looking at some of those areas that I alluded to.
So is all this kind of a merger of, certainly you have the radiation machines that are increasingly more sophisticated, computer technology, new targeting devices, if you will, or homing devices and then the expertise of radiation oncology, which of course continues to advance. Is it all these things coming together?
It is a pretty exciting time. It is a very exciting time. You now have new technology that allows you to deliver increasingly sophisticated patterns of radiation. You have new technology that allows you to aim from all kinds of different angles and crossfire things. And the piece that pulls it together very nicely is the piece that allows you to be sure that you're in the right spot all the time. So when you put these technologies together it makes a pretty compelling story for improving the outlook for a lot of folks who need radiation for a variety of malignancies.